“…Despite the fact that AMPs have shown a promising future in overcoming antibiotic resistance, several obstacles, such as insufficient bioactivities, high toxicity, susceptibility to protease degradation, and high production costs, continue to impede AMPs' further development as commercially available drugs. Numerous strategies have been suggested to increase the antimicrobial potency and lessen the toxicity of AMPs, including template modification, minimalist de novo design, and designbased AMP libraries (Ong et al, 2014;Tan et al, 2020;Yang et al, 2020;Li et al, 2021;Wang C. et al, 2021;Wang Z. et al, 2021). Moreover, a variety of strategies have been investigated to increase the proteolytic stability of AMPs, including sequence changes, peptidomimetics, cyclization, N-methylation, PEGylation, lipidation, and glycosylation (Lai et al, 2022).…”